are glp 1 going away GLP-1 drugs already changing dining-out habits, study finds Compounded GLP-1 ban: What providers

The versions of the weight loss drugs made by compounding pharmacies dont have the same approval from the U.S

Chemical & Physical Properties Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : MC0556000 CHEMICAL NAME : Glycine, N-(N-L-gamma-glutamyl-L-cysteinyl)- CAS REGISTRY NUMBER : 70-18-8 LAST UPDATED : 199710 DATA ITEMS CITED : 20 MOLECULAR FORMULA : C10-H17-N3-O6-S MOLECULAR WEIGHT : 307.36 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4020 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 2238 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 1250 mg/kg SEX/DURATION : female 1-22 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g

In case of CKD, the use of a GLP-1RA with proven cardiovascular benefit is only recommended in those who have not achieved individualized glycemic targets despite SGLT2i treatment, or in whom SGLT2is are contraindicated or not tolerated [6, 8]

Biochemistry (Mosc)